帕金森氏症药物市场：按类型、药物类别、分销管道、最终用途分类 - 全球预测 2023-2030

帕金森氏症药物的全球市场预计将以 8.26% 的年复合成长率大幅增长，到 2023 年达到 66.702 亿美元，预计到 2030 年将达到惊人的 116.4103 亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球帕金森氏症药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球帕金森氏症药物市场规模及预测为何？

2.在预测期内，COVID-19对全球帕金森氏症治疗药物市场的阻碍因素和影响为何？

3.预测期内全球帕金森氏症药物市场需要投资哪些产品/细分市场/应用/领域？

4.你们在全球帕金森氏症药物市场的竞争策略是什么？

5.全球帕金森氏症药物市场的技术趋势和法律规范是什么？

6.全球帕金森氏症药物市场主要厂商的市占率是多少？

7. 哪些型态和策略性措施被认为适合进入帕金森氏症药物全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 高龄化人口中帕金森氏症患者病率增加
    • 开发新的治疗方法和新的侵入性设备
    • 强大的药物管线正在临床研究中
  • 抑制因素
    • 替代治疗的可用性
  • 机会
    • 政府研发步伐加快
    • 专利到期为製药公司带来的可能性
  • 任务
    • 帕金森氏症药物副作用
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章帕金森氏症药物市场：依类型

• 肠内注射
• 口服
• 皮下的
• 经皮的

第7章依药物类别分類的帕金森氏症药物市场

• 抗胆碱能作用
• 卡比多巴/左旋多巴
• COMT抑制剂
• 多巴胺受体激动剂
• 单胺氧化酶抑制剂

第8章帕金森氏症药物市场：按分销管道

• 医院药房
• 网路药房
• 零售药房

第9章帕金森氏症药物市场：依最终用途

• 诊所
• 医院

第10章美洲帕金森氏症药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第11章亚太帕金森氏症药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第12章欧洲、中东和非洲帕金森氏症药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第13章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第14章上市公司名单

第15章附录

• 讨论指南
• 关于许可证和定价

The Global Parkinson's Disease Therapeutics Market is forecasted to grow significantly, with a projected USD 6,670.20 million in 2023 at a CAGR of 8.26% and expected to reach a staggering USD 11,641.03 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Parkinson's Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Parkinson's Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Transdermal is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Dopamine Receptor Agonist is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Retailer Pharmacy is projected to witness significant market share during forecast period.

Based on End Use, market is studied across Clinic and Hospital. The Hospital is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Parkinson's Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Parkinson's Disease Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Parkinson's Disease Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Parkinson's Disease Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Parkinson's Disease Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Parkinson's Disease Therapeutics Market?

6. What is the market share of the leading vendors in the Global Parkinson's Disease Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Parkinson's Disease Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Parkinson's Disease Therapeutics Market, by Type, 2022 vs 2030
• 4.3. Parkinson's Disease Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.4. Parkinson's Disease Therapeutics Market, by Distribution Channel, 2022 vs 2030
• 4.5. Parkinson's Disease Therapeutics Market, by End Use, 2022 vs 2030
• 4.6. Parkinson's Disease Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of Parkinson's disease among aging population
    • 5.1.1.2. Development of new therapies and minimally invasive new devices
    • 5.1.1.3. Strong drug pipeline under clinical research
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of alternative treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing pace of R&D by the government
    • 5.1.3.2. Potential for pharmaceutical companies due to patent expiry
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects of Parkinson's drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Parkinson's Disease Therapeutics Market, by Type

• 6.1. Introduction
• 6.2. Intestinal Infusion
• 6.3. Oral
• 6.4. Subcutaneous
• 6.5. Transdermal

7. Parkinson's Disease Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Anticholinergic
• 7.3. Carbidopa/Levodopa
• 7.4. COMT Inhibitor
• 7.5. Dopamine Receptor Agonist
• 7.6. MAO Inhibitor

8. Parkinson's Disease Therapeutics Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacy
• 8.3. Online Pharmacy
• 8.4. Retailer Pharmacy

9. Parkinson's Disease Therapeutics Market, by End Use

• 9.1. Introduction
• 9.2. Clinic
• 9.3. Hospital

10. Americas Parkinson's Disease Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Parkinson's Disease Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
• FIGURE 5. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 7. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2022 VS 2030 (%)
• FIGURE 8. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
• FIGURE 10. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 5. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 10. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 20. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 153. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
• TABLE 190. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 191. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 192. PARKINSON'S DISEASE THERAPEUTICS MARKET LICENSE & PRICING